Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. - Wikidata - wikimedia - TriplyDB

Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

http://www.wikidata.org/entity/Q39733170

about

Pancreatic cancer stem cell markers and exosomes - the incentive push A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy CD151-A Striking Marker for Cancer Therapy The CD9/CD81 tetraspanin complex and tetraspanin CD151 regulate α3β1 integrin-dependent tumor cell behaviors by overlapping but distinct mechanisms Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer CD151 restricts the α6 integrin diffusion mode.Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer.Correlations between transmembrane 4 L6 family member 5 (TM4SF5), CD151, and CD63 in liver fibrotic phenotypes and hepatic migration and invasive capacities Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by α3β1 versus α6β4 integrin.Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling.Diminished metastasis in tetraspanin CD151-knockout mice.Integrin α3β1 as a breast cancer target CD151: Basis Sequence: Mouse.Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer.Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes.Palmitoylation by DHHC3 is critical for the function, expression, and stability of integrin α6β4 The mesenchymal tumor microenvironment: a drug-resistant niche.CD151 represses mammary gland development by maintaining the niches of progenitor cells.Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis Tetraspanin CD151 plays a key role in skin squamous cell carcinoma.Knockdown of cathepsin B and uPAR inhibits CD151 and α3β1 integrin-mediated cell adhesion and invasion in glioma CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion.CD151 promotes α3β1 integrin-dependent organization of carcinoma cell junctions and restrains collective cell invasion Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression.CD151-mediated adhesion is crucial to osteosarcoma pulmonary metastasis.The extracellular matrix in digestive cancer Tetraspanin protein contributions to cancer.Tetraspanin CD151 as a target for antibody-based cancer immunotherapy.Targeting tetraspanins in cancer.CD151 in cancer progression and metastasis: a complex scenario.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Laminin Modulates the Stem Cell Population in LM05-E Murine Breast Cancer Cells Through the Activation of the MAPK/ERK Pathway.GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.Integrin α3β1-CD151 complex regulates dimerization of ErbB2 via RhoA.Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.

P2860

Q26741215-BA80EBAA-5AEB-4E35-AA37-1712E1B75E62 Q26824462-8CEDA492-0B92-48AB-BDF2-5D2CCCA2C01E Q27024979-1C29C793-374B-4B1F-8B22-DC1BD0FB2F6A Q27324066-55F42FA4-DD32-46C0-A022-DC3840C00DD7 Q28488566-7C2DCAA3-E741-412B-952D-370A1BE2CDD2 Q30513779-5256FEDD-FC19-4AF4-8686-9515B21F80A4 Q33559314-DC8823D3-6261-465B-B551-4BD70E37FAF9 Q33916621-84DBF300-FEDB-42D0-BC1C-4F85C7979E0D Q34032403-880671B2-3F51-4898-88C5-AF4B18F790E4 Q34606382-6A80D265-DE77-44E2-87FF-1D541A2A949D Q34914039-FC38779B-E998-4805-BBEA-15CF5EA1E9EC Q34946846-B0D946F4-F0A5-4378-892D-AECB8484D8E2 Q35067887-C2457056-1455-4757-87D8-631BA22EDB2E Q35112273-697B0A77-6710-49B8-B102-39C1B7F9FBCC Q35539262-AAE5786B-B6A8-4F74-8BEC-BDBACCA60A85 Q35609661-188CCB7F-DC45-400C-B92E-F1B9FA27EB92 Q35785330-82233114-2828-45BD-90EB-99823F43184C Q35803226-34472595-2983-4EF3-ADFF-02FC4A8CC531 Q35837603-D8157B3B-C158-42FC-BA12-3D21EBACC30E Q35967522-278FA20C-1860-4754-BE04-C1259C1C92FB Q36120647-E671B43C-BE7F-4C25-8E6E-60150DEF9DEC Q36187755-6F85A4B6-052A-4990-89ED-567C6E3C7C55 Q36188917-0CB41CE2-B5E0-48FE-903C-331CA3B1DD8D Q36200408-04EB3045-707E-402C-8DEC-DE72E64AD909 Q36350751-C87062D3-22DE-47D8-ABFB-8390F068EF98 Q36476417-03B69551-6DDB-4A3A-BE59-5F12158478F8 Q36557409-461D8C2C-4A3A-4839-B2EF-FE2BC5EDFCEE Q36838910-284B6C3C-077A-4127-8773-E2D8E9784B4C Q37626182-DF561199-2A4D-4B2A-9861-0F8BCFBB89FA Q37645073-41DC11B0-0B58-43DF-AFF1-835725EC3E14 Q37826353-BF7E1A9D-13A7-406A-8A7F-9C99D39224DA Q37856398-EDA32639-6119-47EA-B86E-263A7E610515 Q37856399-419C04CE-659D-4983-B1A4-FD9A22F27043 Q38033584-03A59A3B-7974-4D16-B42C-22A48A3F8E3B Q38163831-528A0798-2709-43BF-9350-1A6F9FEE4B68 Q38269966-23203E8A-7F77-4C7B-AA5B-D196B29A902F Q38722973-15AD5B91-2E72-4440-841E-9AFF6902A6C4 Q38895410-10AD79BF-6BA8-487B-B9D8-DE432FA237AC Q39136410-38142A71-028B-47EB-971D-81D2E55D5F32 Q42032794-00244E7E-08AE-4645-8FF2-91D5F55FD32B

P2860

Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

http://www.wikidata.org/entity/Q39733170

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Disruption of laminin-integrin ...... er cells to ErbB2 antagonists.

@en

Disruption of laminin-integrin ...... er cells to ErbB2 antagonists.

@nl

type

label

Disruption of laminin-integrin ...... er cells to ErbB2 antagonists.

@en

Disruption of laminin-integrin ...... er cells to ErbB2 antagonists.

@nl

prefLabel

Disruption of laminin-integrin ...... er cells to ErbB2 antagonists.

@en

Disruption of laminin-integrin ...... er cells to ErbB2 antagonists.

@nl

P1433

Q39733170-8610B08F-F0AC-4A52-8933-E8D2393BDB3E

P1476

Q39733170-054DA3C0-CE18-4D1A-B93F-9766662679E0

P2093

Q39733170-08EC94C7-6A9C-44FC-BA99-528F2FFBBD13

Q39733170-122FA57B-3015-412F-85E3-A465A6F80DC5

Q39733170-70842639-6534-43F9-B0DB-D2A0A9D06B7A

Q39733170-83828137-C761-4D3D-88C7-63591CE4311E

Q39733170-A472D57C-E566-4E04-BDB4-CA8844345D8B

Q39733170-F859A648-09C8-405C-B2CB-11762FC70E32

P2860

Q39733170-087C2512-4AE1-4C0D-AC0A-9E30B01D2E8D

Q39733170-0901A133-F89A-4F3E-85BD-F0F1EFF005B9

Q39733170-101F989C-E012-413F-89C3-0695C860EBF7

Q39733170-1936D1B5-D3DC-4261-A559-2AFD37834CD9

Q39733170-1BADD91D-07A7-440A-A77E-B2B5688F7FF1

Q39733170-1F522CAD-97E1-4D1B-9977-A85D427C85B3

Q39733170-2E54E0D7-7192-4261-ABDB-BDC1DEBFE4DA

Q39733170-2FA5E137-2170-4603-8365-F96AF10202BA

Q39733170-45E6D517-F12E-400F-8177-1C5D0EB8F511

Q39733170-494C540A-83D5-438D-9B23-C92EE2FBC642

P304

Q39733170-517E0117-57A3-4B65-9F79-4CF8E1E630A5

P31

Q39733170-8ACD36A8-E7A0-4C47-8C89-088FA29C630F

P356

Q39733170-CF31DFEB-58CA-45A2-9A29-676B03373470

P407

Q39733170-ED1064EC-4F94-4E97-ACB1-22C2A35EA928

P433

Q39733170-D6CF9781-36A2-4275-A871-F896FE82DEBD

P478

Q39733170-7C622170-00BC-4259-8545-D42DFC495230

P50

Q39733170-FF44ADC5-9666-40E5-83DB-19291FF93EBA

P577

Q39733170-129AC40D-C652-4D6A-AD9B-9410076D35B1

P698

Q39733170-C461EB18-A8DF-4FC9-806E-134015DCC1A0

P932

Q39733170-A4D3FC66-412A-4758-AB67-148E407521B5

P356

0008-5472.CAN-09-4032

P1433

Cancer Research

P1476

Disruption of laminin-integrin ...... cer cells to ErbB2 antagonists

@en

P2093

Fenghui Xu

http://www.w3.org/2001/XMLSchema#string

Ian E Krop

http://www.w3.org/2001/XMLSchema#string

Ludmila M Flores

http://www.w3.org/2001/XMLSchema#string

Martin E Hemler

http://www.w3.org/2001/XMLSchema#string

Pengcheng Zhou

http://www.w3.org/2001/XMLSchema#string

Xiuwei H Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

Focal adhesion kinase: the first ten years

Focal adhesion kinase: in command and control of cell motility

ERBB receptors and cancer: the complexity of targeted inhibitors

Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro.

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.

P304

2256-2263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-4032

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20197472

http://www.w3.org/2001/XMLSchema#string

P932

3310185

http://www.w3.org/2001/XMLSchema#string